Literature DB >> 16611017

Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment.

Pedro J Modrego1.   

Abstract

BACKGROUND: Mild Cognitive Impairment is a common condition defined as transitional state between normality and dementia of Alzheimer type. Clinically is characterized by subjective and objective memory loss beyond the expected for age and educational level, although a broad range of cognitive inefficiencies may appear, with preservation of daily living activities. Approximately half the patients convert to dementia within 3 years. Since no all patients convert to dementia it is essential to find reliable predictors so as to start the appropriate treatment as soon as possible.
METHOD: Extensive Medline-based search for articles dealing with predictors of conversion to dementia in Mild Cognitive Impairment (MCI).
RESULTS: There is a substantial body of literature dealing with predictors of dementia in patients with MCI. These predictors range from a simple delayed recall task on Mini-Mental to sophisticated radiological techniques and CSF biomarkers. Comprehensive neuropsychological tests rarely surpass 70% sensitivity and specificity. The presence of the APOE epsilon 4 allele has been associated with increased risk of conversion but the sensitivity is quite low. CSF biochemical markers are being developed with encouraging results. beta-amyloid 42 protein is usually lower in converters than in people with stable cognitive status and tau protein is higher. The sensitivity is substantial but specificity is so far low. An epitope of tau protein (P231) looks more specific of Alzheimer's disease and therefore a promising biomarker. In the blood, high beta-amyloid protein levels indicate risk of conversion but only a few studies have been published. Hippocampal or entorhinal atrophy on MRI is one of the most used radiological markers of conversion but quantification of atrophy is not simple as it is subject to artifacts and anatomic variations. Proton Magnetic Resonance Spectroscopy (MRS) and Positron Emission Tomography (PET) are emerging as the most promising predictive tools. The highest degree of accuracy (>90%) has been achieved by means of PET plus either memory performance or APOE4 genotype. However, the samples of the published studies are mostly small, and these instruments are not widely available.
CONCLUSIONS: There is no enough evidence to recommend specific techniques for predictions. Until an accurate marker is developed, a combined use of cognitive tests, APOE genotype, and a neuroradiological technique is probably the best option for prediction purposes depending on availability and experience.

Entities:  

Mesh:

Year:  2006        PMID: 16611017     DOI: 10.2174/156720506776383103

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  30 in total

1.  Cognitive, genetic, and brain perfusion factors associated with four year incidence of Alzheimer's disease from mild cognitive impairment.

Authors:  Montserrat Alegret; Gemma Cuberas-Borrós; Ana Espinosa; Sergi Valero; Isabel Hernández; Agustín Ruíz; James T Becker; Maitée Rosende-Roca; Ana Mauleón; Oscar Sotolongo; Joan Castell-Conesa; Isabel Roca; Lluís Tárraga; Mercè Boada
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  Prediction of conversion from mild cognitive impairment to Alzheimer disease based on bayesian data mining with ensemble learning.

Authors:  R Chen; K Young; L L Chao; B Miller; K Yaffe; M W Weiner; E H Herskovits
Journal:  Neuroradiol J       Date:  2012-03-01

3.  Potential beneficial effects of low molecular weight heparin on cognitive impairment in elderly patients on haemodialysis.

Authors:  Milenka Sain; Vedran Kovacic; Josipa Radic; Dragan Ljutic; Ivo Jelicic
Journal:  Drugs Aging       Date:  2012-01-01       Impact factor: 3.923

4.  Abnormal integrity of corticocortical tracts in mild cognitive impairment: a diffusion tensor imaging study.

Authors:  Hyun Cho; Dong Won Yang; Young Min Shon; Beum Saeng Kim; Yeong In Kim; Young Bin Choi; Kwang Soo Lee; Yong Soo Shim; Bora Yoon; Woojin Kim; Kook Jin Ahn
Journal:  J Korean Med Sci       Date:  2008-06       Impact factor: 2.153

Review 5.  The clinical use of structural MRI in Alzheimer disease.

Authors:  Giovanni B Frisoni; Nick C Fox; Clifford R Jack; Philip Scheltens; Paul M Thompson
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

Review 6.  Genetics and functional imaging: effects of APOE, BDNF, COMT, and KIBRA in aging.

Authors:  Goran Papenberg; Alireza Salami; Jonas Persson; Ulman Lindenberger; Lars Bäckman
Journal:  Neuropsychol Rev       Date:  2015-02-10       Impact factor: 7.444

7.  Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment.

Authors:  A Caroli; C Testa; C Geroldi; F Nobili; L R Barnden; U P Guerra; M Bonetti; G B Frisoni
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

8.  High-dimensional pattern regression using machine learning: from medical images to continuous clinical variables.

Authors:  Ying Wang; Yong Fan; Priyanka Bhatt; Christos Davatzikos
Journal:  Neuroimage       Date:  2010-01-04       Impact factor: 6.556

9.  Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort.

Authors:  Shannon L Risacher; Andrew J Saykin; John D West; Li Shen; Hiram A Firpi; Brenna C McDonald
Journal:  Curr Alzheimer Res       Date:  2009-08       Impact factor: 3.498

10.  The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers.

Authors:  Manuel Fernández Martínez; Xabier Elcoroaristizabal Martín; Luís Galdos Alcelay; Jessica Castro Flores; Juan María Uterga Valiente; Begoña Indakoetxea Juanbeltz; María Angeles Gómez Beldarraín; Josefa Moraza López; María Carmen Gonzalez-Fernández; Ana Molano Salazar; Rocio Bereincua Gandarias; Sandra Inglés Borda; Nuria Ortiz Marqués; Miryam Barandiarán Amillano; María Carrasco Zabaleta; Marian M de Pancorbo
Journal:  BMC Neurosci       Date:  2009-09-30       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.